IFNA17 and chronic myelogenous leukemia, BCR-ABL1 positive: Our results show that, in CML patients, IFNα treatment modulates and potentiates the in vivo host immunologic compartment and paves the way to the optimization of immunotherapeutic strategies aimed at achieving and maintaining a DMR as a possible pre-requisite for TKI discontinuation.